Inovio Pharmaceuticals (INO) Current Leases (2019 - 2026)

Inovio Pharmaceuticals has disclosed Current Leases across 8 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Current Leases rose 9.14% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.9 million (up 9.14% YoY), while the FY2025 annual figure was $2.8 million, up 13.02% from the prior year.
• Current Leases came in at $2.9 million for Q2 2026 at Inovio Pharmaceuticals, roughly flat from $2.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.9 million in Q1 2026 to a low of $2.1 million in Q3 2023.
• Average Current Leases over 5 years is $2.6 million, with a median of $2.6 million recorded in 2023.
• Year-over-year, Current Leases decreased 24.92% in 2023 and gained 19.48% in 2025.
• Over 5 years, Current Leases stood at $2.8 million in 2022, then fell by 14.17% to $2.4 million in 2023, then gained by 3.77% to $2.5 million in 2024, then increased by 13.02% to $2.8 million in 2025, then gained by 2.71% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $2.9 million in Q2 2026, $2.9 million in Q1 2026, and $2.8 million in Q4 2025.